HK1074434A1 - Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid - Google Patents

Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid

Info

Publication number
HK1074434A1
HK1074434A1 HK05105456A HK05105456A HK1074434A1 HK 1074434 A1 HK1074434 A1 HK 1074434A1 HK 05105456 A HK05105456 A HK 05105456A HK 05105456 A HK05105456 A HK 05105456A HK 1074434 A1 HK1074434 A1 HK 1074434A1
Authority
HK
Hong Kong
Prior art keywords
lewis acid
inhibiting
degradation
methods
fluoroether
Prior art date
Application number
HK05105456A
Other languages
English (en)
Inventor
Christopher Bieniarz
Steve H Chang
Keith R Cromack
Shuyen L Huang
Toshikazu Kawai
Manami Kobayashi
David Loffredo
Rajagopalan Raghavan
Earl R Speicher
Honorats A Stelmach
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25148366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1074434(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of HK1074434A1 publication Critical patent/HK1074434A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Catalysts (AREA)
  • Steroid Compounds (AREA)
HK05105456A 1997-01-27 2005-06-29 Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid HK1074434A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/789,679 US5990176A (en) 1997-01-27 1997-01-27 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid

Publications (1)

Publication Number Publication Date
HK1074434A1 true HK1074434A1 (en) 2005-11-11

Family

ID=25148366

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05105456A HK1074434A1 (en) 1997-01-27 2005-06-29 Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid

Country Status (28)

Country Link
US (6) US5990176A (fr)
EP (2) EP1114641B1 (fr)
JP (5) JP3183520B2 (fr)
KR (1) KR100368672B1 (fr)
CN (3) CN1152674C (fr)
AR (2) AR011090A1 (fr)
AT (2) ATE201987T1 (fr)
AU (1) AU726733B2 (fr)
BG (2) BG109751A (fr)
BR (1) BR9806996A (fr)
CA (2) CA2626424A1 (fr)
CO (1) CO4920220A1 (fr)
CZ (1) CZ297092B6 (fr)
DE (2) DE69833884T2 (fr)
DK (2) DK1114641T3 (fr)
ES (2) ES2170474T3 (fr)
GR (1) GR3036190T3 (fr)
HK (1) HK1074434A1 (fr)
HU (1) HUP0002101A3 (fr)
IL (1) IL130150A (fr)
NO (1) NO993606L (fr)
NZ (1) NZ335994A (fr)
PL (1) PL334477A1 (fr)
PT (2) PT967975E (fr)
SK (1) SK284243B6 (fr)
TR (1) TR199901579T2 (fr)
WO (1) WO1998032430A1 (fr)
ZA (1) ZA98418B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
US20030200963A1 (en) * 1998-01-09 2003-10-30 Flament-Garcia Mary Jane Container for an inhalation anesthetic
US6074668A (en) * 1998-01-09 2000-06-13 Abbott Laboratories Container for an inhalation anesthetic
US6162443A (en) * 1998-01-09 2000-12-19 Abbott Laboratories Container for an inhalation anesthetic
DK1105096T3 (da) * 1998-08-19 2004-03-08 Skyepharma Canada Inc Injicerbare vandige propofoldispersioner
EP1530336B1 (fr) 1999-01-08 2009-06-10 Sony Deutschland GmbH Structure de préambule de synchronisation pour système MDFO
TW523409B (en) 2000-09-15 2003-03-11 Baxter Int Container for inhalation anesthetic
BR0303489A (pt) * 2003-09-10 2005-07-05 Cristalia Prod Quimicos Farm Composição farmacêutica estabilizada de composto flúor-éter e método para inibir a degradação de composto flúor-éter. uso de agente estabilizante para inibir a degradação de composto flúor éter
US7816409B2 (en) * 2003-09-10 2010-10-19 Cristalia Productos Quimicos Farmaceuticos Ltda Stable pharmaceutical composition of fluoroether compound for anesthetic use method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound
AP2007004229A0 (en) * 2005-04-18 2007-12-31 Minrad Inc Preparation of sevoflurane with negligible water content
WO2009049460A1 (fr) * 2007-10-15 2009-04-23 Jiangsu Hengrui Medicine Co., Ltd. Nouveau matériau conditionné de sévoflurane
AU2009206390B2 (en) * 2008-01-22 2014-10-30 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US20090275785A1 (en) 2008-05-01 2009-11-05 Barry Jones Distillation Method For The Purification Of Sevoflurane And The Maintenance Of Certain Equipment That May Be Used In The Distillation Process
US8563115B2 (en) * 2008-08-12 2013-10-22 Xerox Corporation Protective coatings for solid inkjet applications
US8092822B2 (en) * 2008-09-29 2012-01-10 Abbott Cardiovascular Systems Inc. Coatings including dexamethasone derivatives and analogs and olimus drugs
US8283643B2 (en) * 2008-11-24 2012-10-09 Cymer, Inc. Systems and methods for drive laser beam delivery in an EUV light source
US8191992B2 (en) * 2008-12-15 2012-06-05 Xerox Corporation Protective coatings for solid inkjet applications
US9278048B2 (en) * 2009-05-06 2016-03-08 Baxter International, Inc. Pharmaceutical product and method of use
US9102604B1 (en) 2010-02-15 2015-08-11 Baxter International Inc. Methods for cleaning distilling columns
CN105106182B (zh) * 2015-09-21 2017-12-29 山东新时代药业有限公司 七氟烷吸入剂
CN105193774B (zh) * 2015-09-21 2018-01-16 山东新时代药业有限公司 一种七氟烷吸入剂
CA2952552C (fr) * 2016-11-02 2018-05-15 Central Glass Company, Limited Methode de lavage de contenant de stockage de sevoflurane et methode de stockage de sevoflurane

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2992276A (en) * 1959-05-20 1961-07-11 Du Pont Process for preparing polyfluoro alkyl compounds
US3527813A (en) * 1966-10-03 1970-09-08 Air Reduction 1,1,2 - trifluoro - 2 - chloroethyl difluoromethyl ether and its method of preparation
US3689571A (en) * 1970-07-31 1972-09-05 Baxter Laboratories Inc Fluorinated ether
GB1499818A (en) * 1974-12-06 1978-02-01 Ici Ltd Anaesthetic composition
US4250334A (en) * 1979-12-26 1981-02-10 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
US4469898A (en) * 1979-12-26 1984-09-04 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
JP2786108B2 (ja) 1994-03-31 1998-08-13 セントラル硝子株式会社 フルオロメチル−１，１，１，３，３，３−ヘキサフルオロイソプロピルエーテルの精製方法
IT1270239B (it) * 1994-06-17 1997-04-29 Zambon Spa Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid

Also Published As

Publication number Publication date
DE69833884T2 (de) 2006-08-24
SK86199A3 (en) 2000-06-12
CN1321958C (zh) 2007-06-20
CO4920220A1 (es) 2000-05-29
JP2005279283A (ja) 2005-10-13
EP0967975B1 (fr) 2001-06-13
ATE201987T1 (de) 2001-06-15
SK284243B6 (sk) 2004-12-01
EP1114641A2 (fr) 2001-07-11
CN1899271A (zh) 2007-01-24
JP2001187729A (ja) 2001-07-10
IL130150A (en) 2004-09-27
CA2626424A1 (fr) 1998-07-30
KR100368672B1 (ko) 2003-01-24
AU5930098A (en) 1998-08-18
HUP0002101A2 (hu) 2001-05-28
JP3183520B2 (ja) 2001-07-09
DK0967975T3 (da) 2001-09-17
EP1114641B1 (fr) 2006-03-22
DE69833884D1 (de) 2006-05-11
US20060148906A1 (en) 2006-07-06
GR3036190T3 (en) 2001-10-31
CN1244797A (zh) 2000-02-16
BG109751A (bg) 2008-06-30
NO993606L (no) 1999-09-24
JP2006137769A (ja) 2006-06-01
CZ256199A3 (cs) 1999-11-17
EP0967975A1 (fr) 2000-01-05
CN1560003A (zh) 2005-01-05
ES2256104T3 (es) 2006-07-16
DE69800928T2 (de) 2001-11-22
NO993606D0 (no) 1999-07-23
JP2006143742A (ja) 2006-06-08
PL334477A1 (en) 2000-02-28
BG103656A (en) 2000-04-28
EP1114641A3 (fr) 2003-05-28
PT1114641E (pt) 2006-05-31
DE69800928D1 (de) 2001-07-19
TR199901579T2 (xx) 1999-12-21
US6677492B2 (en) 2004-01-13
BG65414B1 (bg) 2008-07-31
US6288127B1 (en) 2001-09-11
AU726733B2 (en) 2000-11-16
NZ335994A (en) 2000-08-25
KR20000070482A (ko) 2000-11-25
JP2000510159A (ja) 2000-08-08
US20040048932A1 (en) 2004-03-11
US5990176A (en) 1999-11-23
US6444859B2 (en) 2002-09-03
DK1114641T3 (da) 2006-05-15
BR9806996A (pt) 2000-03-14
CN1152674C (zh) 2004-06-09
JP3664648B2 (ja) 2005-06-29
CZ297092B6 (cs) 2006-09-13
US20030130359A1 (en) 2003-07-10
ES2170474T3 (es) 2002-08-01
ATE320798T1 (de) 2006-04-15
WO1998032430A1 (fr) 1998-07-30
CA2278133C (fr) 2001-06-26
HUP0002101A3 (en) 2002-03-28
AR011090A1 (es) 2000-08-02
PT967975E (pt) 2001-11-30
ZA98418B (en) 1999-04-20
CA2278133A1 (fr) 1998-07-30
IL130150A0 (en) 2001-03-19
US20020016373A1 (en) 2002-02-07
AR057610A2 (es) 2007-12-05

Similar Documents

Publication Publication Date Title
GR3036190T3 (en) Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid
PL313821A1 (en) Analogues of distamycin a as anticarcinogenic and antiviral agents
HU9603592D0 (en) Aryl-sulfonamido-hydroxamic acids of matrix-metalloproteinase-inhibiting activity
AU2337197A (en) Cinnamic acid derivatives and their use as integrin antagonists
ES2194679T3 (es) Composiciones cosmeticas que contienen creatina, carnitina y/o acido piruvico.
NZ279397A (en) Mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives and pharmaceutucal compositions
YU41199A (sh) Hinoksalindioni
MY115071A (en) Efficacy enhancer for agricultural chemicals and agricultural chemical compositions
MY118918A (en) Solid and semisolid compositions for reducing tooth erosion
AU1843397A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
HU9401584D0 (en) Preparation of substituted piperidines
EE9900022A (et) Värvuskompositsioon, mis koosneb pürogalloolstruktuure sisaldavast agendist, raud(II)soolast ning orgaanilisest happest
GB2362103B (en) Pharmaceutical compositions including alginates
CA2127374A1 (fr) Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent
TW262460B (fr)
ZA951013B (en) Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
DK0617027T3 (da) N-benzylpiperazinforbindelser, fremgangsmåde til fremstilling heraf og sammensætninger indeholdende forbindelserne
NO20013499D0 (no) Farmasöytisk blanding omfattende en kombinasjon av en profen og andre aktive forbindelser
AU4647999A (en) Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and alkanoyl l-carnitines
CA2352597A1 (fr) Compositions de fluoroether et procedes d'inhibition de leur degradation en presence d'un acide de lewis
AU575758B2 (en) Decahydroquinolinol derivatives
IT1265045B1 (it) Composizione farmaceutica atta a inibire la sintesi della lipoproteina (a)

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20180122